Healio Uveitic Macular Edema: Enhancing Visual Outcomes Through the Use of Corticosteroid Delivery Systems
Uveitic macular edema (UME) is the leading cause of visual impairment in patients with uveitis, particularly in patients with noninfectious uveitis. Noninfectious uveitis affects up to 30% of patients with uveitis and can lead to vision-threatening complications, such as macular ischemia, if left untreated. Corticosteroids remain the first-line treatment, delivered via systemic, periocular, or intravitreal routes, but their long-term use is limited by significant ocular and systemic adverse effects. Advances in treatment, such as long-acting intravitreal corticosteroid implants, immunomodulatory therapies, and novel delivery systems like suprachoroidal injections, have improved outcomes by reducing adverse effects and enhancing visual acuity and macular anatomy. Despite these advancements, treatment regimens remain challenging due to limited robust evidence, variability in patient response, and adverse event profiles. In this CE activity, expert faculty compare corticosteroid delivery systems based on dosage, administration, and the ability to personalize treatment. They also review the latest clinical evidence for UME treatments and their ability to improve long-term outcomes.
Cost: Free
View Offer chevron_rightDetails
Uveitic macular edema (UME) is the leading cause of visual impairment in patients with uveitis, particularly in patients with noninfectious uveitis. Noninfectious uveitis affects up to 30% of patients with uveitis and can lead to vision-threatening complications, such as macular ischemia, if left untreated. Corticosteroids remain the first-line treatment, delivered via systemic, periocular, or intravitreal routes, but their long-term use is limited by significant ocular and systemic adverse effects. Advances in treatment, such as long-acting intravitreal corticosteroid implants, immunomodulatory therapies, and novel delivery systems like suprachoroidal injections, have improved outcomes by reducing adverse effects and enhancing visual acuity and macular anatomy. Despite these advancements, treatment regimens remain challenging due to limited robust evidence, variability in patient response, and adverse event profiles. In this CE activity, expert faculty compare corticosteroid delivery systems based on dosage, administration, and the ability to personalize treatment. They also review the latest clinical evidence for UME treatments and their ability to improve long-term outcomes.
Topics Covered
Uveitic Macular Edema
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Compare corticosteroid delivery systems based on their dosage, administration, and ability to personalize UME treatment.
- Select treatment for patients with UME based on the latest clinical evidence and ability to improve long-term outcomes.
Target Audience
The intended audience for this activity is retina specialists and other healthcare professionals involved in the management of patients with UME.
Additional credit info
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.